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Abstract: “Nonallergic vasomotor rhinitis” (also referred to as
nonallergic rhinitis and/or idiopathic rhinitis) is a term that has been
used to describe a common nasal condition of unclear pathophysi-
ology. Clinical options for patients are limited by a lack of straight-
forward diagnostic criteria and poorly defined and heterogeneous
populations in clinical trials. A roundtable conference convened in
December 2008 addressed these challenges. Part 1 of the proceed-
ings of that meeting provided a consensus definition of “nonallergic
rhinopathy,” proposed to replace the former terms above based on
the clinical characteristics of the disease, which were described in
individual papers. Part 2 of the proceedings uses the revised defi-
nition for a consensus discussion on appropriate criteria for enrolling
subjects in future clinical studies of the efficacy of potential treat-
ments for this disease.
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INTRODUCTION
“Nonallergic vasomotor rhinitis” (also referred to as non-allergic rhinitis and/or idiopathic rhinitis) is a term that
has been used to describe a common nasal condition of
unclear pathophysiology. Clinical options for patients are
limited by a lack of straightforward diagnostic criteria and
poorly defined and heterogeneous populations in clinical
trials. A roundtable conference convened in December 2008
addressed these challenges. Chaired by Michael A. Kaliner,
MD, the consensus meeting included James N. Baraniuk,
MD; Michael Benninger, MD; Jonathan A. Bernstein, MD;
Phil Lieberman, MD; Eli O. Meltzer, MD; Robert M. Nacle-
rio, MD; and Russell A. Settipane, MD. Each expert partic-
ipant presented a State of the Art paper on a topic related to
what is currently known about the pathophysiology, epide-
miology, diagnostic criteria, and treatment options. The pre-
sentations were followed by discussion and counterpoint
leading to 2 consensus statements—one on the definition and
the other on the study criteria. Our goal was to work toward
improving understanding of the phenotypes to identify ac-
ceptably homogeneous populations for studying the underly-
ing mechanisms and developing better therapies. The pro-
ceedings of that meeting are summarized herein and include
the findings, discussion, and recommendations.
The proceedings have been divided into 2 parts. Part 1,
published in the June issue of the journal started with an
overview of the classification of nonallergic rhinitis syn-
dromes and the proposal to change the terminology to refer-
ence these as “nonallergic rhinopathy;” it concluded with the
after consensus definition of the new term. “Nonallergic
rhinopathy (NAR) is a chronic nasal condition with symp-
toms that may be perennial, persistent, intermittent or sea-
sonal and/or elicited by recognized triggers. There are a well
recognized set of clinical exposures that lead to the symp-
toms, predominantly congestion, rhinorrhea and postnasal
drip.” NAR is defined by clinical characteristics that are
described in detail in Part 1 of these proceedings.
The variable symptomatology and triggers of NAR
have led to confusion about specific diagnostic testing and
appropriate treatment options. These challenges are discussed
in Part 2 of the proceedings, presented here, and include
review of the major classes of medications used to treat these
patients. Discussion culminated in a consensus statement and
specific suggestions for acceptable diagnostic criteria to per-
mit precise identification of patients for participation in future
clinical trials of potential therapies for this disease. The
criteria are based on the clinical characteristics described in
the first part of the proceedings.
As the proceedings from the meeting are read, please
keep in mind that the older terminology (vasomotor rhinitis,
nonallergic rhinitis) remains in the individual papers as they
were written and submitted before the consensus discussion.
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